FDA Alerts Health Care Professionals and Oncology Clinical Investigators About Two Clinical Trials on Hold Evaluating KEYTRUDA® (pembrolizumab) in Patients With Multiple Myeloma
Aug 30
2017
Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration (FDA) today issued a statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of KEYTRUDA® (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. KEYTRUDA® (pembrolizumab) is not approved for treatment of multiple myeloma.
